Short Interest in Indivior PLC (NASDAQ:INDV) Increases By 17.4%

Indivior PLC (NASDAQ:INDV - Get Free Report) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 1,420,000 shares, a growth of 17.4% from the January 15th total of 1,210,000 shares. Based on an average daily trading volume, of 1,200,000 shares, the short-interest ratio is presently 1.2 days. Currently, 1.2% of the company's stock are sold short.

Indivior Stock Up 0.7 %

Shares of Indivior stock traded up $0.08 during trading on Wednesday, reaching $10.91. The company's stock had a trading volume of 1,791,728 shares, compared to its average volume of 1,116,808. Indivior has a 1-year low of $7.33 and a 1-year high of $23.22. The company has a 50-day simple moving average of $11.56 and a two-hundred day simple moving average of $10.89. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -272.63 and a beta of 0.73.

Hedge Funds Weigh In On Indivior

Hedge funds have recently modified their holdings of the stock. VELA Investment Management LLC grew its position in Indivior by 722.9% during the 3rd quarter. VELA Investment Management LLC now owns 123,435 shares of the company's stock worth $1,212,000 after purchasing an additional 108,435 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Indivior in the 4th quarter valued at $359,000. Stifel Financial Corp purchased a new position in Indivior in the 3rd quarter worth $100,000. AlphaCentric Advisors LLC acquired a new stake in Indivior during the 3rd quarter worth about $2,364,000. Finally, Clark Estates Inc. NY purchased a new stake in Indivior during the 3rd quarter valued at about $2,477,000. Institutional investors and hedge funds own 60.33% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on INDV. RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Rodman & Renshaw started coverage on Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 target price on the stock. Finally, Piper Sandler reissued an "overweight" rating and set a $16.00 price target (up from $15.00) on shares of Indivior in a research report on Friday, October 25th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.